Analyst Price Targets — JBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 15, 2026 9:30 am | — | UBS | $45.00 | $15.34 | TheFly | Jade Biosciences initiated with a Buy at UBS |
| June 2, 2026 10:54 am | — | Piper Sandler | $55.00 | $18.59 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $55 at H.C. Wainwright |
| June 2, 2026 10:51 am | Vamil Divan | Guggenheim | $47.00 | $18.59 | TheFly | Jade Biosciences price target raised to $47 from $32 at Guggenheim |
| May 11, 2026 11:46 am | Laura Chico | Wedbush | $34.00 | $25.81 | TheFly | Jade Biosciences price target raised to $34 from $24 at Wedbush |
| May 11, 2026 11:24 am | — | Guggenheim | $32.00 | $25.81 | TheFly | Jade Biosciences price target raised to $32 from $23 at Guggenheim |
| April 27, 2026 10:14 am | — | H.C. Wainwright | $45.00 | $24.98 | TheFly | Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright |
| March 6, 2026 5:15 pm | Alex Thompson | Stifel Nicolaus | $40.00 | $14.07 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" |
| January 7, 2026 11:07 am | — | H.C. Wainwright | $25.00 | $13.17 | TheFly | Jade Biosciences initiated with a Buy at H.C. Wainwright |
| October 9, 2025 10:22 am | — | BTIG | $28.00 | $9.08 | TheFly | Jade Biosciences initiated with a Buy at BTIG |
| June 16, 2025 12:17 am | Vamil Divan | Guggenheim | $14.00 | $6.76 | TheFly | Jade Biosciences upgraded to Buy from Neutral at Guggenheim |
Latest News for JBIO
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to…
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of…
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JBIO.
U.S. House Trading
No House trades found for JBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.